Skip to main content
logo
Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
82.54
-0.76 (-0.91%)
At close: Jul 31, 2026, 4:00 PM EDT
82.57
+0.03 (0.04%)
After-hours: Jul 31, 2026, 7:34 PM EDT

Halozyme Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
348.84316.89444.09281.59202.13402.71
Depreciation & Amortization
101.3488.0581.3184.8649.643
Stock-Based Compensation
57.5351.5743.3936.6224.420.82
Other Adjustments
14.22347.31-0.4524.1752.39-130.07
Change in Receivables
-151.44-128.06-74.25-3.34-83.946.76
Changes in Inventories
30.522.55-67.38-26.88-17.487.37
Changes in Accounts Payable
-27.936.2146.99-12.5524.541.17
Changes in Unearned Revenue
-----2.49-0.75
Changes in Other Operating Activities
-37.07-32.965.364.1-9.06-11.56
Operating Cash Flow
677.42651.56479.06388.57240.11299.44
Operating Cash Flow Growth
34.45%36.01%23.29%61.83%-19.81%439.98%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-9.76-6.97-10.7-15.29-4.81-1.46
Sale of Property, Plant & Equipment
----26.01-
Purchases of Investments
-116.56-247.36-647.6-292.91-255.21-652.52
Proceeds from Sale of Investments
681.08722.25395.57211.3746.13247.68
Cash Acquisitions
0.71-1,014---999.12-
Investing Cash Flow
-458.27-545.81-262.72-96.91-487.01-406.29

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
----120-
Short-Term Debt Repaid
-----120-
Long-Term Debt Issued
-1,470--250784.88
Long-Term Debt Repaid
--763.39--13.48-327.45-369.06
Net Long-Term Debt Issued (Repaid)
-706.61--13.48-77.45415.81
Issuance of Common Stock
-1.6121.8331.147.8814.0512.54
Repurchase of Common Stock
--342.37-250-392.38-200-350.06
Net Common Stock Issued (Repurchased)
-1.61-320.54-218.86-384.5-185.95-337.52
Other Financing Activities
--471.24--625.78-0.42
Financing Cash Flow
-83.47-85.17-218.86-407.99362.3777.87

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
135.6820.57-2.52-116.33115.48-28.98

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
667.65644.59468.37373.28235.3297.98
Free Cash Flow Growth
34.67%37.62%25.47%58.64%-21.04%462.76%
FCF Margin
44.26%46.15%46.13%45.01%35.65%67.22%
Free Cash Flow Per Share
5.485.203.622.781.672.03
Levered Free Cash Flow
405.941,080499.68302.34165816.29
Unlevered Free Cash Flow
411.9375.22495.17307.13257.57444.86
SEC Filings: 10-K · 10-Q